Vertex Pharmaceuticals (VRTX)

SG&A Expense Growth

17.93%

Quarterly · Period ending:

VRTX logo

VRTX SG&A Expense Growth

Latest reported17.93%
VRTX Quarterly SG&A Growth (QoQ) (0.00% → 17.93%)
High-resolution chart · PNG

VRTX sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Vertex Pharmaceuticals SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
17.9259%
1.3758%
9.4136%
4.8281%
7.114%
4.9788%
1.56%
-0.1075%
8.6081%
-7.1525%
39.9166%
0.457%
8.9175%
-9.8355%
8.3468%
14.6307%
0.0465%
-15.674%
28.766%
1.8443%
1.3135%
-9.3305%
14.7883%
-3.7815%
5.2376%
-6.6669%
22.2973%
2.0268%
6.4314%
-4.0239%
11.5918%
-0.0058%
5.7739%
-3.699%
11.6676%
-5.1387%
12.2858%
3.1099%
3.633%
-5.0129%
6.119%
8.4077%
-2.7242%
5.6974%
9.9394%
9.3382%
4.3909%
-2.8691%
4.3578%
-1.2981%
-14.3684%
-17.5712%
14.6879%
-15.9101%
13.0707%
-16.8746%
5.7294%
-8.8078%
10.146%
13.525%
36.2792%
14.4771%
27.8846%
19.4061%
15.0849%
9.1423%
-10.9319%
12.4393%
14.0463%
17.8123%
-10.9673%
-5.8811%
33.6031%
-7.7989%
9.5069%
-8.1725%
41.0292%
4.4134%
7.2091%
2.8045%
11.577%
0.5308%
19.3053%
-0.7028%
12.3299%
-17.4144%
9.9717%
4.3307%
4.5052%
30.4266%
-25.2657%
-2.2349%
-10.9151%
-4.7175%
-7.0313%
-3.1465%
20.3064%
6.7545%
-13.3267%
17.8361%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.